Bicalutamide 150 mg plus standard care vs standard care alone for early prostate cancer

BJU International

Volumn 97, Issue 2, 2006, Pages 247-254

  McLeod, David G ^a   Iversen, Peter ^b   See, William A ^c   Morris, Thomas ^d   Armstrong, Jon ^d   Wirth, Manfred P ^e  

^a WALTER REED ARMY MEDICAL CENTER   (United States)

^b Rigshospitalet   (Denmark)

^c MEDICAL COLLEGE OF WISCONSIN   (United States)

^d ASTRAZENECA   (United Kingdom)

^e DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

Author keywords

Adjuvant; Antiandrogen; Bicalutamide; Localized; Locally advanced; Prostate cancer

Indexed keywords

ANTIANDROGEN; BICALUTAMIDE; PLACEBO; ANILIDE;

AGED; ARTHRALGIA; ARTICLE; ASTHENIA; BACKACHE; CANCER ADJUVANT THERAPY; CANCER GRADING; CANCER LOCALIZATION; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER RISK; CANCER STAGING; CAUSE OF DEATH; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE FREE INTERVAL; DISEASE FREE SURVIVAL; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG ERUPTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; EARLY CANCER; EVALUATION; GYNECOMASTIA; HAZARD ASSESSMENT; HOT FLUSH; HUMAN; IMPOTENCE; LIVER FUNCTION TEST; MAJOR CLINICAL STUDY; MALE; MASTALGIA; OVERALL SURVIVAL; PHARYNGITIS; PRIORITY JOURNAL; PROSTATE CARCINOMA; PROSTATECTOMY; RANDOMIZED CONTROLLED TRIAL; SAMPLE SIZE; ADJUVANT CHEMOTHERAPY; DISEASE COURSE; METHODOLOGY; MULTICENTER STUDY; MULTIMODALITY CANCER THERAPY; PROSTATE TUMOR; SURVIVAL;

AGED; ANDROGEN ANTAGONISTS; ANILIDES; CHEMOTHERAPY, ADJUVANT; COMBINED MODALITY THERAPY; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; DOUBLE-BLIND METHOD; HUMANS; MALE; NEOPLASM STAGING; PROSTATECTOMY; PROSTATIC NEOPLASMS; SURVIVAL ANALYSIS;

EID: 33644857333     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2005.06051.x     Document Type: Article

References (22)

1. Aus G Abbou CC Bolla M et al. European Association of Urology Guidelines on Prostate Cancer. Accessed November, 2005
2. Pilepich MV Winter K Lawton CA et al. Androgen suppression adjuvant to definitive radiotherapy in carcinomas of the prostate - long-term results of Phase III RTOG 85-31 Int J Radiat Oncol Biol Phys 2005 61 1285 90
3. Bolla M Collette L Blank L et al. Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial Lancet 2002 360 103 6
4. Hanks GE Pajak TF Porter A et al. Phase III trial of long-term adjuvant androgen deprivation after neoadjuvant hormonal cytoreduction and radiotherapy in locally advanced carcinoma of the prostate: the Radiation Therapy Oncology Group Protocol 92-02 J Clin Oncol 2003 21 3972 8
5. Messing E Manola J Sarosdy M Wilding G Crawford ED Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadenectomy in men with node positive prostate cancer: results at 10 years of EST 3886 J Urol 2003 169 396 A1480
6. Kirby R Treatment options for early prostate cancer Urology 1998 52 948 62
7. Messing EM Manola J Sarosdy M Wilding G Crawford ED Trump D Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadenectomy in men with node-positive prostate cancer N Engl J Med 1999 341 1781 8
8. Daniell HW Dunn SR Ferguson DW Lomas G Niazi Z Stratte PT Progressive osteoporosis during androgen deprivation therapy for prostate cancer J Urol 2000 163 181 6
9. Sieber PR Keiller DL Kahnoski RJ Gallo J McFadden S Bicalutamide 150 mg maintains bone mineral density during monotherapy for localized or locally advanced prostate cancer J Urol 2004 171 2272 6
10. Green HJ Pakenham KI Headley BC et al. Quality of life compared during pharmacological treatments and clinical monitoring for non-localized prostate cancer: a randomized controlled trial BJU Int 2004 93 975 9
11. Smith MR Eastham J Gleason DM Shasha D Tchekmedyian S Zinner N Randomized controlled trial of zoledronic acid to prevent bone loss in men receiving androgen deprivation therapy for nonmetastatic prostate cancer J Urol 2003 169 2008 12
12. Smith MR McGovern FJ Zietman AL et al. Pamidronate to prevent bone loss during androgen-deprivation therapy for prostate cancer N Engl J Med 2001 345 948 55
13. Sculpher M Bryan S Fry P de Winter P Payne H Emberton M Patients' preferences for the management of non-metastatic prostate cancer: discrete choice experiment BMJ 2004 328 382
14. Iversen P Tyrrell CJ Kaisary AV et al. Bicalutamide monotherapy compared with castration in patients with nonmetastatic locally advanced prostate cancer: 6.3 years of followup J Urol 2000 164 1579 82
15. Boccardo F Rubagotti A Barichello M et al. Bicalutamide monotherapy versus flutamide plus goserelin in prostate cancer patients: results of an Italian Prostate Cancer Project study J Clin Oncol 1999 17 2027 38
16. D'Amico AV Manola J Loffredo M Renshaw AA DellaCroce A Kantoff PW 6-month androgen suppression plus radiation therapy versus radiation therapy alone for patients with clinically localized prostate cancer: a randomized controlled trial JAMA 2004 292 821 7
17. Wirth MP Weissbach L Marx FJ et al. Prospective randomized trial comparing flutamide as adjuvant treatment versus observation after radical prostatectomy for locally advanced, lymph node-negative prostate cancer Eur Urol 2004 45 267 70
18. See WA Wirth MP McLeod DG et al. Bicalutamide as immediate therapy either alone or as adjuvant to standard care of patients with localized or locally advanced prostate cancer: first analysis of the early prostate cancer program J Urol 2002 168 429 35
19. Wirth MP See WA McLeod D Iversen P Morris T Carroll K. Bicalutamide 150 mg in addition to standard care in patients with localized or locally advanced prostate cancer: results from the second analysis of the early prostate cancer program at median followup of 5.4 years J Urol 2004 172 1865 70
20. Stephenson RA Prostate cancer trends in the era of prostate-specific antigen. An update of incidence, mortality, and clinical factors from the SEER database Urol Clin North Am 2002 29 173 81
21. Tyrrell CJ Payne H Tammela TL et al. Prophylactic breast irradiation with a single dose of electron beam radiotherapy (10 Gy) significantly reduces the incidence of bicalutamide-induced gynecomastia Int J Radiat Oncol Biol Phys 2004 60 476 83
22. Saltzstein D Sieber P Morris T Gallo J Prevention and management of bicalutamide-induced gynecomastia and breast pain: randomized endocrinologic and clinical studies with tamoxifen and anastrozole Prostate Cancer Prostatic Dis 2005 8 75 83